Abstract:Background and Purpose Two clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis (MG) patients who fitted Myasthenia Gravis Foundation of America (MGFA) Class II and Class III. Methods We performed an 18-month prospective, randomized, open-labeled trial of prednisone combined with MTX 10 mg orally every week versus prednisone alone in 40 recently diagnosed MG patients of MGFA Class II and Class III between July 2014 and July 2018. The primary endpoint was the prednisone area under the dose–time curve (AUDTC) from months 3 to 18. Secondary endpoints included changes of the Quantitative Myasthenia Gravis Score (QMG), the Myasthenia Gravis Activity of Daily Living Score (MG-ADL), initial time of prednisone reduction, the median prednisone daily dose in each month, adverse events, and treatment failures in each group. Results Forty participants were included; among those, 5 individuals withdrew. A total of 35 participants completed 18 months of follow-up (18 in prednisone+MTX, 17 in prednisone group). Combined use of MTX reduced the month 3–18 prednisone AUDTC (prednisone+MTX 5,663.44 ± 1,678.08 mg, prednisone 6,683.94 ± 678.08 mg, p = 0.03, 95% confidence interval -1916.01 to -124.98). The initial times of prednisone reduction were 4.34 ± 1.44 months in the prednisone+MTX group and 5.56 ± 2.05 months in the prednisone group ( p = 0.04, 95% CI -2.41 to -0.03). The median daily prednisone dose was significantly lower in the prednisone+MTX group at month 6 and months 9–18. No significant differences were found in QMG and MG-ADL scores between the two groups. No serious drug-related adverse events were observed in both groups. Conclusions This study provides evidence that MTX has the steroid-sparing ability in generalized MG patients of MGFA Class II and Class III. Clinical Trial Registration http://www.chictr.org.cn/showproj.aspx?proj=10563 identifier ChiCTR-IPR-15006081.

Therapeutic Effects of High-dose Methylprednisolone Combined with Azathioprine on Immune Function in Patients with Myasthenia Gravis

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis

Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Immunosuppressive and Monoclonal Antibody Treatment for Myasthenia Gravis: A Network Meta-Analysis.

A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis

Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis

The Therapeutic Mechanism of Tacrolimus on Myasthenia Gravis

Effectiveness and Safety of Mycophenolate Mophetil in Myasthenia Gravis: A Real-Life Multicenter Experience

Plasma Levels and Clinical Significance of Complement Activation Products in Generalized Myasthenia Gravis Patients with Acetylcholine Receptor Antibodies

Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients

A study of therapeutic efficacy of mycophenolate mofetil in the treatment of multiple sclerosis ;and neuromyelitis optica

Effect of High Dose Intravenous Methylprednisolone in Retractable Ocular Myasthenia Gravis

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

Methylprednisolone Modulates the Tfr/Tfh ratio in EAE-Induced Neuroinflammation through the PI3K/AKT/FoxO1 and PI3K/AKT/mTOR Signalling Pathways

In vitro modulation of T cells in myasthenia gravis by low-dose IL-2

Acupuncture and moxibustion treatment for myasthenia gravis: A systematic review and meta-analysis

Optimal time for the addition of non-corticosteroid immunosuppressants in myasthenia gravis: a single-center retrospective study in China

Traditional Chinese medicine improves myasthenia gravis by regulating the symbiotic homeostasis of the intestinal microbiota and host